Introduction Leqembi® Arrives in China for Alzheimer’s Care Eisai, in partnership with BioArctic AB, has announced China’s approval of Leqembi® (乐意保), a groundbreaking treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease. Following its success in the United States and Japan, this approval marks a significant stride in global healthcare. Understanding Alzheimer’s and…
In a groundbreaking move poised to reshape the landscape of brain disease treatments, CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) has announced the successful completion of its merger with EIP Pharma Inc. This milestone marks the birth of a dynamic clinical-stage biotechnology company committed to advancing innovative therapies for degenerative diseases. The company’s press…
Introduction Eli Lilly recently presented the full results from their Phase 3 TRAILBLAZER-ALZ 2 study at the Alzheimer’s Association International Conference (AAIC). The study focused on evaluating the effectiveness of donanemab, a potential treatment for early symptomatic Alzheimer’s disease (AD). The results, also published in the Journal of the American Medical Association (JAMA), demonstrated that…